News

Bavarian Nordic closes site
Enlarge image

BusinessDenmarkGermany

Bavarian Nordic closes site

14.01.2013 - Danish Bavarian Nordic A/S has announced the consolidation of its manufacturing activities at company headquarters in Kvistgaard.

With the aim of optimising productivity and profitability, all batches for clinical trials will be manufactured in Denmark, as well as the company’s prostate cancer vaccine PROSTVAC®. As a consequence, Bavarian Nordic will close its operations in Berlin, Germany where it has been producing clinical trial material for its MVA-BN based vaccine candidates. 

The company said it is seeking to further improve the profitability of the current and future expected contracts with the U.S. Government to manufacture and deliver it MVA-BN-based smallpox vaccine IMVAMUNE®. Bavarian Nordic is currently in an argument with the US government Denmark's biggest drugmaker accuses its customer not to fulfil the conditions of a 2007 contract  worth US$500m. Last November, however, the US government signed two new contracts with the company. The restructuring of its production allows Bavarian Nordic a more flexible manufacturing approach and reduces dependence on subcontractors, thus providing the company full control of pre-launch activities for PROSTVAC®. At the Kvistgaard facility, functions to support the production development of PROSTVAC® are already in place and the preparatory work thus requires only modest investments.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/bavarian-nordic-restructures-production.html

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

FinancingGermany

10.03.2015 The Gates Foundation has dipped into its purse to bring infectious diseases vaccines to the poorest countries. German vaccine specialist CureVac is set to receive US$52m for their mRNA platform technology.

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.54 CHF14.07%
  • SYNGENTA329.00 CHF0.27%
  • 4SC0.84 EUR0.00%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • BASILEA110.00 CHF-2.65%
  • ACTELION114.70 CHF-1.88%

TOP

  • CYTOS1.54 CHF352.9%
  • MEDIGENE13.50 EUR217.6%
  • FORMYCON26.00 EUR55.7%

FLOP

  • WILEX2.92 EUR-14.9%
  • BASILEA110.00 CHF-10.0%
  • MORPHOSYS70.55 EUR-5.6%

TOP

  • SANTHERA95.40 CHF2346.2%
  • WILEX2.92 EUR386.7%
  • FORMYCON26.00 EUR273.6%

FLOP

  • CYTOS1.54 CHF-49.7%
  • 4SC0.84 EUR-37.3%
  • THERAMETRICS0.07 CHF-36.4%

No liability assumed, Date: 26.03.2015